SAN DIEGO--(BUSINESS WIRE)--Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO) member of Blood Centers of America (BCA), today announced that it has been selected ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
CAR-T therapies have proven their curative potential, but cell therapy developers continue to face challenges related to manufacturing complexities, costs, scalability, regulatory compliance, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results